drugset / Trial / NCT03220425

Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.

NCT03220425

Phase 3 Completed 752 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-label

Summary

The aim of this trial is to evaluate the efficacy and safety of insulin detemir using the 2400 nmol/mL formulation to optimise dosing in subjects with type 1 diabetes on a basal (once daily)-bolus regimen.

Timeline

Start
2001-02-01
Primary completion
2001-11-12
Completion
2001-11-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Protein / enzyme biologic
Subject insulin detemir Protein / enzyme biologic